Q-Med Has Obtained Registration Approval For Restylane(R) In China

Main Category: GastroIntestinal / Gastroenterology
Also Included In: Regulatory Affairs / Drug Approvals;  Pediatrics / Children's Health
Article Date: 08 Jan 2009 - 8:00 PDT

email to a friend   printer friendly   opinions  

Q-Med (STO:QMED) has obtained registration approval for Restylane® in China. An application for sales approval will be submitted shortly and it is estimated that sales of the product will begin at the end of the second quarter in 2009.

"There is a large appetite for new things in China and great respect for products from the West. We are therefore very pleased about this registration approval, which means that Restylane® will be the first hyaluronic acid product intended for the cosmetic market in China", says Bengt Ågerup, Q-Med´s President and CEO.

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane™ for body contouring, Durolane™ for the treatment of osteoarthritis of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta™ for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.

Q-Med AB

• Additional
• References
• Citations